In spite of this, up-regulation of certain SUMO machinery components associated with favorable treatment response in some cases such as UBE2I 10920CG genotype enhances sensitivity to irinotecan chemotherapy in lung cancer through upregulation of SUMO1 in tumor cells (40). This evidence concerns the gene SUMO1 and lung carcinoma.